The male mammary glands often undergo hyperplasia in the presence of tumors associated with a high urinary excretion of chorionic gonadotropin. Included in this group are the chorioepitheliomas, both testiculari'3 and extragenital,"" and, more rarely, teratomas"' and seminomas""' of the testis. Although the histological and clinical features differ in each of these tumors, there is reason to believe that all contain chorionic elements when accompanied by chorionic gonadotropin in the urine."2 Less commonly gynecomastia occurs in association with non-choriogenic tumors of the testis. These comprise a heterogeneous group with respect to their hormonal excretion patterns, but in general fall into one of two categories: (i) those in which the gynecomastia is probably a non-specific effect related to loss of testicular tissue by tumor invasion, radiation therapy, or surgical extirpation,' and in which the excretion of androgen is low and of follicle-stimulating gonadotropic hormone (FSH) high,' and (ii) those in which the gynecomastia appears to be more directly related to hormonal stimulation by the tumor itself, as in Sertoli-cell'0 and aberrant adrenocortical'1 tumors. In these the excretion of estrogen is increased, and since removal of the tumor results in both a reduction in urinary estrogen and a regression in the gynecomastia, it is highly probable that the tumor is the source of the estrogen and that the latter is an important factor in stimulating mammary growth. Gynecomastia has also been reported as a rare complication in interstitial-or Leydig-cell tumors,"' but the histological diagnosis in such cases has been questioned.' As a rule these tumors produce virilization in children, but exert no hormonal effects in adults.3' On the basis of a study of dog tumors, Huggins and Moulder' have presented evidence to show that those testicular tumors associated with gynecomastia and previously reported as interstitial-cell tumors were probably incorrectly interpreted examples of Sertoli-cell tumors. However, in one of these cases, that of Hunt and Budd," the possibility of chorionic elements in the tumor does not appear to have been completely excluded, since the urine contained
The contributions of Hamburger and his associates7' '9 have shed considerable light on the relationships between testicular tumors and the urinary gonadotropins. These investigators were the first to point out the necessity for distinguishing between the excretion of luteinizing chorionic gonadotropin derived from certain types of testicular tumor tissue, and the excretion of follicle-stimulating gonadotropin originating in the anterior lobe of the pituitary in response to a decrease in androgen secretion, related to non-specific testicular injury. They clearly demonstrated that only in the case of the choriogenic tumors is extirpation followed by a decrease in gonadotropin excretion. Moreover, they attempted to correlate the type of gonadotropin excreted with the histological features and clinical course of the tumors they studied, and concluded that the excretion of chorionic gonadotropin was characteristic of radioresistant, mixed epitheliomas, a group of tumors including chorioepitheliomas and embryonal adenocarcinomas, 27 and that it denoted a bad prognosis, while the excretion of FSH in increased amounts was characteristic of radiosensitive seminomas and indicative of a more favorable outlook. Further studies by FuruhjelmM and Twombly27 have confirmed the different sites of origin and significance of the two types of gonadotropin, but have not corroborated the close correlation between the type of gonadotropin present in the urine and the histological features of the tumor reported by Hamburger. However, it is well recognized that the structure of the testicular tumors, and especially of their metastases, is often not uniform, and it is highly probable that chorionic elements are always present when the urine contains chorionic gonadotropin.1 '27 Ever since Cooke2 first called attention to the occurrence of gynecomastia in chorioepithelioma in 1915, the subject of its pathogenesis has been a matter of speculation and debate. Unfortunately, not even the great strides made in endocrinology since then have added materially to Cooke's original hypothesis that the gynecomastia is probably the result of stimulation by a substance present both in chorioepitheliomatous tissue and the normal placenta. It is now known, of course, that several analogous, if not identical, hormones can be isolated from each of these tissues, but whether, in the case of testicular chorioepithelioma, any one of these hormones stimulates the mammary gland directly or exerts its effects indirectly by activating other endocrine glands, is still unknown. It is reasonably certain, however, from cases like Warthin's,"7 in which the gynecomastia subsided after the tumor had been removed and recurred when metastases made their appearance, and from cases of extragenital chorioepithelioma with gynecomastia,`42 that the gynecomastia is related to the humoral activity of the tumor and not to the coincidental testicular atrophy which is often present.
Most authors'
'-' ascribe the gynecomastia to a direct estrogen effect, and certainly the frequency with which hyperestrinuria has been demonstrated" 17-I ahd the similarity between the type of mammary duct hyperplasia found in chorioepithelioma and that produced by estrogen' appear to support this hypothesis. However, there is no unanimity of opinion regarding the origin of this estrogen. Many'9' ' consider it to be a secretory product of the tumor itself because of the high estrogen levels found in some chorioepitheliomas.' 8 Others regard the testis as the source of estrogen, basing this opinion on the experiments of Geschickter and his associates,' who showed that chorionic gonadotropin derived from pregnancy urine produced mammary growth in intact male monkeys, but not in castrates, and on the frequent occurrence of interstitial-cell hyperplasia in the unaffected testis in chorioepithelioma.-'19-b'-While the testis may play a r6le in the pathogenesis of gynecomastia in chorioepithelioma, the hyperplastic interstitial cells can hardly be taken as evidence of increased estrogen production in the light of present knowledge concerning their androgenproducing function. Finally, it has been suggested1"' that the adrenal cortex may be the source of estrogen under the influence of chorionic gonadotropin stimulation. Certainly there is evidence that some adrenocortical derivatives are estrogenic,' and that the adrenal cortex may be stimulated by chorionic gonadotropin.' Moreover, Ferguson' has reported the occurrence of swelling and hyperemia of the adrenals in cases of teratoma of the testis with elevated urinary gonadotropins. However, this has not been found with any degree of regularity," 2 ' 4' 9, 11, 14' 15, M, 2nor can the possibility be excluded that the adrenocortical hyperplasia in such cases is the result rather than the cause of hyperestrinemia, an effect well recognized in animals.""'
The pituitary is enlarged in many cases of chorioepithelioma and shows changes in the cellular pattern of its anterior lobe resembling those of pregnancy. '8'5 " 8 10-13 16 , W" This has led Gilbert' and others to suggest that the development of gynecomastia may be a pituitary effect. Although this hypothesis is consistent with the mammogen theory of breast development once held by Turner and his associates," more recent work 4'" indicates that the pituitary may exert a potentiating or sensitizing effect, but that it does not promote mammary growth directly.
In a significant number of chorioepitheliomas the mammary glands go on to alveolar development5"0" and the secretion of a colostrum-like material,2'" St Ifeatures not seen ordinarily after estrogen administration, but highly suggestive of a progesterone effect. The possibility that progesterone may be implicated has been considered, and, indeed, pregnandiol has been recovered from the urine in several instances.13' l9 However, it is unlikely that progesterone is the primary factor, since, except in the mouse,6 it does not produce proliferation of the duct system.w0
It is obvious from the preceding discussion that the pathogenesis of choriogenic gynecomastia is still far from well understood, and that further hormone assays and morphological studies of the endocrine system in such cases are not likely to add materially to what is already known. Only the experimental approach appears to offer any hope of solving this problem, and since the response of the mammary gland to hormonal stimuli varies in different species it would be highly desirable to conduct these studies in man. Recently we were afforded an opportunity to carry out such experiments and these are the subject of the present report. They were undertaken following the chance observation, made during the course of some studies of endocrine function in a patient with Laennec's cirrhosis, that massive doses of chorionic gonadotropin produced gynecomastia. Similar effects were observed in a second case of cirrhosis and in two carefully selected controls, one with marked congenital atrophy or aplasia of the testis, and the other with marked pituitary deficiency, but not in two other subjects. Parallel studies of hormone excretion and of the histological changes in the testes and mammary glands were carried out. While the results of these experiments fail to elucidate the pathogenesis of choriogenic gynecomastia, they do clarify several disputed issues, and, more important, point the way for further similar studies.
ExPERIMENTAL SUBJECTS
Seven subjects were studied in the manner to be described-six males and a female control. Cases 1 and 2 were young cirrhotics who develope4 gynecomastia following the administration of chorionic gonadotropin. Case 3, a young cirrhotic who also had congenital ( ?) testicular atrophy, was selected for study to determine whether the testes were essential for this action of chorionic gonadotropin. Since gynecomastia failed to develop in this subject, case 4, a young man with congenital ( ?) atrophy or aplasia of the testes but without evidence of liver disease, was investigated as a control for case 3, and also to determine whether the presence of liver disease was essential for the mammary effect of chorionic gonadotropin. Case 5, a young man with severe pituitary deficiency, was selected for study to determine whether the effects of chorionic gonadotropin were mediated through the pituitary. Case 6 was a presumably normal male control with respect to his endocrine system and liver; however, biopsy of the testis revealed some degree of hypoplasia. Case 7 was a middle-aged female with cirrhosis who served as a control for the hormone excretion studies in the six male subjects investigated. Case 1. Laennec's cirrhosis. E.R., V-47 149, a 32-year-old white, married male, had a history of chronic alcoholism and poor diet for an indeterminate number of years. Cirrhosis was discovered three years before the present study, following an hematemesis. Hematemesis recurred a year later and again shortly before admission to the hospital. Loss deep and the penis appeared normal, measuring 8 cm. in length, but the scrotum was unusually small and contained 2 small ovoid masses measuring 2 x 1 x 1 cm. each. These were assumed to be testes, but on two occasions when they were biopsied only epididymal tissue was obtained. The biopsies were carried out on opposite sides by two different surgeons, the second being a urological specialist who was aware of the previous failure to obtain testicular tissue. It is highly probable, therefore, that there was little or no testicular tissue present. In keeping with this assumption was the observation that a sample of semen contained no spermatozoa. The prostate appeared to be of normal size. The remainder of the examination revealed no other abnormalities.
Laboratory studies, including tests of liver function, were all within normal limits, except for the results of the urinary hormone assays which will be discussed elsewhere.
It was difficult to classify the nature of the testicular disorder in this case since the entire scrotal contents were not available for study, but in many ways it appeared unique. In some respects it was reminiscent of the prepubertal functional castration described by Heller, Nelson, and Roth,5' but the absence of overt eunuchoidism appeared to exclude this possibility. Similarly, the syndromes of Klinefelter52 and del CostilloTM were considered, but the complete lack of testicular elements did not appear compatible. Conceivably this was an example of testicular aplasia with maintenance of the secondary sex characters by the adrenal cortex, as has been described in rare cases of castration.' Case 5. Pituitary deficiency. J.R., V-48 935, a 37-year-old single, white male, was admitted to the hospital because of attacks of headache and vomiting of several months' duration. One and one-half years previously he had suffered an attack of meningitis, and immediately following had developed typical symptoms of myxedema, loss of facial and body hair, and marked atrophy of the testes associated with complete loss of libido and potency. There was a history of chancre seven years previously, presumably cured following a six months' course of therapy.
The patient exhibited typical signs of severe myxedema. Facial and body hair was very sparse. The skin was coarse, pale and dry and had a fawn-colored pigmentation over the face. The testes were very small and soft and were associated with marked atrophy of the penis and prostate. The fundi, visual fields, and neurological examination revealed nothing of note. The blood pressure was low at all times, ranging between 80/52 and 98/64.
The basal metabolic rate and the serum precipitable iodine were low, the former ranging between -24 and -30 per cent, the latter between 4.1 and 2.7 gamma per cent. The results of the Kepler-Power test were equivocal with respect to adrenal function, but there was no fall in eosinophils following an injection of epinephrine. A single injection of ACTH failed to lower the eosinophil count in four hours, but multiple doses lowered the count slightly in 24 hours. The blood sugar and serum electrolytes were within normal limits. Intravenous glucose and insulin tolerance tests were likewise normal. X-rays of the skull revealed no abnormalities. X-ray of the chest showed the presence of calcified tubercles and hilar nodes. A tuberculin test (P.P.D. first strength) was positive. A histoplasmin skin test was also positive, but the complement fixation test for histoplasmosis was negative. Serological tests for syphilis were negative. The spinal fluid was not examined at this time, but subsequently showed a negative serological test for syphilis; cultures for bacteria and fungi, guinea-pig studies for tubercle bacilli, and inoculation of animals and eggs for viruses all failed to demonstrate any organisms.
There seems to be little doubt that this patient had pituitary deficiency manifested by myxedema, depressed gonadal function, and possibly mild Addison's disease. However, the nature of the pituitary lesion was not determined. The possibility of a tuberculoma was seriously considered, especially when the patient developed a second attack of meningitis some time after these studies were completed. Since then his symptoms have been relieved by substitution therapy with thyroid extract and testosterone proprionate, but the diagnosis still remains in doubt. Case 6. "Normal" male control. S.P., V-54 558, a 39-year-old white male, had been hospitalized for eight months because of multiple sclerosis of three years' duration at the time of these studies.
He was in a good state of nutrition and had a heavy beard and deep masculine voice. The external genitalia were above average in size, the testes measuring 4.3 x 2.2 x 2.7 and 4.7 x 2.4 x 2.9 cm. respectively. The remainder of the physical examination revealed no abnormalities other than signs of advanced multiple sclerosis.
Routine laboratory studies, including tests of liver function, yielded normal results. Case 7. Female cirrhotic control. T.F., N-C 21 233, a 43-year-old white housewife, was admitted to the hospital because of ascites and jaundice of several weeks' duration. There was a history of alcoholism and poor diet for 15 years. A left oophorectomy had been performed at the age of 14, but the menstrual cycles had continued regularly until 14 months previously when they ceased abruptly.
The patient was moderately obese and did not appear ill. There was moderate icterus of the skin. One spider nevus was present on the neck. The liver was greatly enlarged and firm and was associated with moderate ascites and visible portal venous collateral circulation. The spleen, however, was not palpable. The ankles were moderately edematous.
Liver biopsy revealed moderately severe cirrhosis with marked fatty infiltration, and chemical studies indicated moderately severe impairment of liver function (Table 1) . There was a moderate macrocytic anemia. No esophageal varices could be demonstrated by x-ray.
METHODS
Chorionic gonadotropin administration. The preparation used ("A.P.L.," Ayerst, McKenna and Harrison, Limited*) was administered intramuscularly as indicated in Table 2 . This material is extracted from human pregnancy urine by the method of Collip' and is said to consist almost exclusively of luteinizing gonadotropin, although negligible traces of FSH and prolactin may be present; the method of extraction is thought to preclude the presence of steroids.' Liver function tests. The methods used in this laboratory have been described elsewhere. ' Urinary hormone assays. Twenty-four or 48-hour specimens of urine were obtained from the patients with special precautions to insure completeness of collection. No preservative was added, but the urine was kept refrigerated and processed within 24 hours after completion of the collection.
A full or half 24-hour specimen was extracted for assay of 17-ketosteroids, androgens, estrogens, and "estroids," as described by Salter males, 2 to 10 mg. of androsterone equivalent (20 to 100 international units of androgen) per day, and for non-pregnant females, 1 to 10 mg. of androsterone equivalent.
"Estroids" were determined colorimetrically by the modified Kober procedure described by Salter and his associates,', ' using a purified phenolic fraction. Range of values for normal males, 20 to 80 micrograms of estrone equivalent per day and for non-pregnant females, 40 to 120 micrograms.
Estrogen excretion was also estimated biologically in the crude phenolic fraction by a modification of the Marrian and Parkes and Mather methods, as described by Humm, Munson and Salter."1 Range of values for normal males 0.5 to 3.0 micrograms of The normal values cited are based on the experiences of this laboratory. However, it should be emphasized that the values for women are based on more limited experience than those for men, and that a minority of subjects of both sexes yield data somewhat outside the ranges given.
RESULTS
Mamtnmary glands. Four of the six male subjects who were given chorionic gonadotropin developed typical gynecomastia (Table 2 ). These included two of the three patients with Laennec's cirrhosis (cases 1 and 2), the patient with congenital ( ?) atrophy or aplasia of the testes (case 4), and the patient with pituitary deficiency (case 5). Only the cirrhotic with congenital ( ?) atrophy of the testis (case 3) and the "normal" male control (case 6) failed to develop gynecomastia.
The first sign of gynecomastia appeared on the 29th to 53d day of gonadotropin therapy, or following the administration of a total dose of 58,000 to 172,000 international units. It is of interest that the gynecomastia was bilateral in only two of the four subjects (cases 4 and 5), and that in each instance the second mammary gland took considerably longer to undergo hyperplasia than the first, not appearing until the 95th and 56th day of treatment respectively, or following the administration of 195,000 and 290,000 international units. Since cases 1 and 2 received only 68,000 and 58,000 international units, respectively, it is highly probable that they too would have developed bilateral gynecomastia had gonadotropin therapy been continued longer. Similarly, the failure of gynecomastia to develop at all in cases 3 and 6 can probably be attributed to inadequate dosage of chorionic gonadotropin. These subjects received a total of 160,000 and 240,000 international units, respectively, which was significantly less than the 290,000 international units required for the development of gynecomastia in the left mammary gland of case 5.
In three of the four subjects (cases 1, 2, and 4) tenderness on pressure over the areolar area preceded the appearance of a mass in the breast by approximately one week. Only one subject (case 4), however, complained of spontaneous pain. Once the gynecomastia developed, it progressed in size very slowly and ultimately became evident on gross inspection. However, from the very beginning a clearly defined, indurated, firm disc of glandular tissue could be palpated in the subareolar area. In no instance did the breast attain the size seen in the young female at puberty, but in each there was a soft dome-or cone-shaped swelling approximately twice the size of the underlying disc of glandular tissue. (It should be noted that the size of the gynecomastia indicated in Table 2 refers to this disc of tissue.) Except for tenderness, the nipples and areolae exhibited no changes, and none of the subjects developed any secretion.
A biopsy specimen was obtained from the involved breast in three of the subjects (cases 1, 2, and 5). The histological features were essentially the same in all (Fig. 1) (Table 3) . This was most marked in case 5, the patient with pituitary deficiency, who also showed considerable thickening of the basement membrane and peritubular fibrosis ( Fig. 2A) . The basement membrane of the tubules was likewise thickened in the cirrhotics, but to a lesser degree, (Fig. 3A) , and there was slight peritubular fibrosis in the "normal" control (Fig. 4A) . As already mentioned, no testicular tissue was obtained in case 4, and only sections of the epididymal duct showing varying degrees of epithelial atrophy and degeneration were demonstrated (Fig. 5A) .
The Leydig cells appeared to be normal in number, or only slightly decreased, in all but the subject with pituitary deficiency, in whom only rare Leydig cells could be found (Fig. 2A) . In contrast, the number of Sertoli cells was slightly diminished in all cases.
Judging from the findings on subsequent biopsy, the administration of chorionic gonadotropin produced the following effects on the testis: (a) more active spermatogenesis in the cirrhotic (case 1), without any detectable increase in Leydig or Sertoli cells (Fig. 3B) ; (b) no significant change in any of the elements in the patient with pituitary deficiency (Fig.  2B) , and (c) a marked increase in the number of Leydig cells in the "normal" control (Fig. 4B) . Chorionic gonadotropin also appeared to restore the tubular epithelium of the epididymal duct to a normal state in the patient with congenital ( ?) atrophy or aplasia of the testes (Fig. 5B) .
Androgen excretion. As might be expected from previous reports," androgen excretion, judged by the results of both the 17-ketosteroid deter- (Table 4) revealed that, despite marked daily variations, there was a suggestive upward trend in excretion in two of the three male cirrhotics (cases 1 and 2) and in the female cirrhotic control (case 7). On the other hand, neither patient with congenital ( ?) testicular atrophy (cases 3 and 4) showed an increase in 17-ketosteroids.
Too few serial bioassays of androgen were carried out to permit any conclusions, but it is of interest that, whereas in case 1 the 17-ketosteroids rose from an initial level of 5.1 to a peak of 12.6 mg. per day after 82,000 international units of chorionic gonadotropin, androgen excretion remained at the low pretreatment level of 0.5 mg. per day. Similarly, in case 2 there was only a slight rise in androgen excretion, from 0.18 to 0.9 mg. per day, while the 17-ketosteroids increased from 4.4 to 9.5 mg. per day.
Of special interest was the occurrence of symptoms suggesting androgen stimulation in three of the subjects receiving gonadotropin. In one of the cirrhotics (case 2) frequent erections were first noted on the eighth day of therapy, even before there had been any significant increase in 17-ketosteroid excretion. Similarly, in case 4, the patient with congenital (?) atrophy or aplasia of the testes, there was a marked increase in libido and potency in the ninth week of treatment, and, in addition, an unmistakable increase in the beard necessitating more frequent shaving. In case 5, the patient with pituitary deficiency, an increased growth of beard was noted at two weeks, and frequent erections at three weeks. Estrogen excretion. Bioassay of the urine revealed that two of the male cirrhotics (cases 1 and 2) were excreting slightly more estrogen than normal, and during the administration of chorionic gonadotropin the amount increased significantly (Table 4) . Chemically determined "estroids," on the other hand, remained within the normal range, although in case 2 there was a similar tendency to rise during gonadotropin therapy.
Case 3, the cirrhotic with congenital (?) testicular atrophy, had an abnormally high "estroid" excretion. During gonadotropin therapy the level fell transiently and then returned to the initial level. The fall in estrogen excretion could not be correlated with any change in 17-ketosteroids (Table 4) .
Estrogen excretion was within normal limits in case 4, the patient with congenital atrophy or aplasia of the testes, but was abnormally low in case 5, the patient with pituitary deficiency (Table 4) . Unfortunately, it was not possible to carry out serial estrogen assays during gonadotropin therapy in these cases.
The female cirrhotic had an abnormally low level of estrogen excretion, but this rose to within the normal range during chorionic gonadotropin administration (Table 4) .
Gonadotropin excretion. Both subjects with congenital (?) testicular atrophy (cases 3 and 4) and the female cirrhotic (case 7) excreted abnormally large amounts of FSH, no doubt reflecting a "castration effect" on the pituitary (Table 4) . On the other hand, as might be expected, the patient with pituitary deficiency (case 5) excreted very little. In the two cases of uncomplicated cirrhosis, FSH excretion was low in one (case 1) and low normal in the other (case 2). Concomitant with the increase in estrogen excretion noted during gonadotropin therapy in these two cases there was a fall in FSH excretion. This decrease was not noted during gonadotropin therapy in case 4, the patient with congenital ( ?) atrophy or aplasia of the testes; in fact, FSH excretion rose from 70 to > 160 m.u.u. per day. Unfortunately, parallel studies of estrogen excretion were not carried out in this case, so that it cannot be stated whether there was a reciprocal relationship between estrogen and FSH excretion. In view of the wellrecognized fact that estrogen administration will reduce the increased gonadotropin excretion of eunuchoid men,' it is difficult to reconcile the high level of urinary gonadotropin in case 3 with the apparent increase in "estroid" excretion (Table 4) , unless it is assumed that the nature of the compounds from which the latter was derived differed from most of the natural and synthetic estrogens.
Evidently none of the injected chorionic gonadotropin was excreted in the urine in cases 1 and 2 who received 2000 international units daily. This 68 ,000 41 82,000 48 96,000 55 110 is in keeping with the observation of Lloyd and his associates' that it takes at least 5,000 international units in a single dose to produce an increase in urinary gonadotropin in non-pregnant females, and the report of Brown and Bradbury' that it requires daily injections of 10,000 to 20,000 international units to produce a positive Ascheim-Zondek reaction. It is highly probable, however, that the increase in urinary gonadotropin in case 4 was due to the excretion of chorionic gonadotropin, since in this instance the individual doses were 5,000 units administered thrice weekly.
COMMENT The amount of chorionic gonadotropin injected in these experiments was well within the range secreted by the tumor in cases of chorioepithelioma with spontaneous gynecomastia, and was probably less than average considering the large amounts usually excreted in the urine.5 For example, in
Hamburger's case"7 the daily urinary excretion of chorionic gonadotropin was 600,000 international units, and even in a case like Laipply and Shipley's" in which urine contained only 300 mouse units, the secretion of the tumor must have been very much greater considering the fact that only a fraction of injected chorionic gonadotropin is excreted in the urine.' -', Similarly, the duration of chorionic gonadotropin administration in these experiments was well within the range of time it usually takes for gynecomastia to develop in patients with chorioepithelioma. Obviously, it is impossible to determine the age of a tumor precisely, but in the 46 cases reviewed by Gilbert5 there were 25 in which the date of onset of both testicular tumor and gynecomastia was given. In these, gynecomastia appeared on an average of 5.8 months after the presence of the tumor was recognized, and in 14 of the 25 it appeared in 3 months or less.
If the assumption is correct that the chorionic gonadotropin used in these experiments was not contaminated significantly by the other hormones found in human pregnancy urine, it is reasonable to conclude that the spontaneous gynecomastia of chorioepithelioma, like the experimental variety described here, is due to chorionic gonadotropin, and not to the other hormones known to be secreted by chorionic tissue.
Of the possible contaminants found in commercial preparations of chorionic gonadotropin derived from human pregnancy urine, only estrogen, FSH, and prolactin need be considered in connection with possible direct or indirect mammogenic effects. Estrogen can probably be excluded, since it is eliminated by the Collip method of extraction. Traces of FSH and prolactin are known to be present in the preparation used, but it is stated that the amounts are too small to exert any clinical effect.' The relative freedom of "A.P.L." from contaminating FSH has been confirmed by others.7' In the present experiments only the slight increase in spermatogenesis observed in case 1 suggested an FSH effect. However, this could have been due to an increase in androgen, which, under some circumstances, is likewise known to promote spermatogenesis,75 or to the secretion of FSH by the pituitary under the influence of chorionic gonadotropin, as suggested by Evans and Simpson.76 There is evidence that, quite apart from its ability to stimulate lactation in the properly prepared gland, prolactin may also induce growth of the mammary gland.' However, Folley and Malpress,78 who have reviewed this subject suggest that such growth is probably due to the presence in many prolactin preparations of contaminating adrenocorticotropin. It is unlikely, therefore, that prolactin contamination of the chorionic gonadotropin used in these experiments was responsible for the gynecomastia which was produced.
There is no evidence that chorionic gonadotropin is capable of eliciting a growth response in the mammary gland directly, although this possibility has not been completely excluded. It is more likely, however, that its action is mediated through the gonads, the pituitary, or the adrenals.
The evidence presented by Geschickter, Lewis, and Hartman'M would appear to implicate the testis in the mammogenic action of chorionic A90 gonadotropin. These investigators found that chorionic gonadotropin induced mammary growth in the male monkey only when the testes were present, and concluded that this effect was mediated through an increase in estrogen production related to hyperplasia of the interstitial cells of the testes. This conclusion, based on the assumption that the interstitial cells are a source of estrogen and that growth of the mammary duct system is necessarily due to estrogen, is no longer tenable in the light of more recent evidence indicating that the Sertoli cells are the sole source of estrogen in the testis"' and that androgen is also capable of provoking mammary hyperplasia' ' and gynecomastia.8' It must be assumed, therefore, that, in the monkey at least, the mammogenic effects of chorionic gonadotropin are mediated either through the interstitial cells by an increase in androgen secretion, or through the Sertoli cells by an increase in estrogen. However, it does not necessarily follow that the same is true in all species. Thus, for example, Lewis, Turner, and Gomez' were unable to produce growth of the mammary glands in intact male mice with large doses of chorionic gonadotropin.
What role the testes played in the present experiments is still uncertain but the occurrence of gynecomastia in the virtual absence of the testes in case 4, and the failure to demonstrate interstitial-or Sertoli-cell hyperplasia in the other subjects who developed gynecomastia strongly suggest that the mammogenic effects of chorionic gonadotropin were not mediated through the testes. The rise in 17-ketosteroids, on the other hand, which was observed in at least two of these subjects (cases 1 and 2) might be construed as evidence of testicular stimulation. However, an adrenal origin for these steroids cannot be excluded, especially since there was no concomitant increase in bioassayable androgen, and since there was an equivalent increase in 17-ketosteroid excretion in the female control. The observations of Reifenstein and his associates' may be pertinent in this connection. These investigators described a 27-year-old man with congenital absence of functioning testicular tissue whose 17-ketosteroid excretion was high. This increased transiently, following the administration of chorionic gonadotropin and was interpreted as evidence of compensatory adrenal cortical hyperplasia. Similarly, the maintenance of secondary sex characteristics' and the delayed rise in 17-ketosteroid excretion following castration' have been ascribed to an increase in adrenal cortical activity.
The evidence presented strongly suggests that the mammogenic effects of chorionic gonadotropin observed in the present experiments were not mediated through the testes, but it cannot be regarded as conclusive, since it was not possible to preclude with certainty the presence of testicular remnants in case 4.
The frequency with which hyperplasia of the pituitary is found in cases A more convincing case can be made for the participation of the adrenal cortex in the development of choriogenic gynecomastia. That the adrenal cortex may, under some conditions, play a role in mammary growth is indicated by the development of gynecomastia both in association with adrenal cortical tumors"" and following the administration of adrenal cortical extract' and desoxycorticosterone acetate.' There is also evidence that, in the hypophysectomized squirrel at least, chorionic gonadotropin is capable of stimulating the adrenal cortex,"0 and the enlargement of the adrenals noted in cases of testicular tumor associated with a high gonadotropin output' is suggestive of a similar effect in man. The secretion of colostrum2'" and the development of alveoli5'10"' in cases of choriogenic gynecomastia point to a progesterone effect, which is confirmed by the presence of pregnandiol in the urine.'-9,' The adrenal cortex is a likely source of this material in the male but the presence of progesterone in placental tissue" suggests the chorioepithelioma itself as an alternative source. Support for the latter possibility is perhaps to be found in the observation that none of the experimental subjects who received chorionic gonadotropin alone developed mammary alveoli or secretion.
While the hypothesis that the mammogenic effects of chorionic gonadotropin may be mediated through the adrenal cortex is an attractive one, it must be pointed out that chorionic gonadotropin does not stimulate the adrenal cortex in all species,' nor do all cases of choriogenic gynecomastia show adrenal hyperplasia.""' 1, 14 15, 21. 22 The effects of chorionic gonadotropin on the adrenal cortex in man have not been studied very extensively. Kyle and O'Donovan' administrated 62,000 international units over a period of 26 days to a young woman with pituitary hypogonadism and "adrenal androgen deficiency," and observed a slight increase in 17-ketosteroid excretion, which was accompanied by nodular hyperplasia of the mammary glands and cornification of the vaginal mucosa. The latter were interpreted as estrogenic effects indicative of ovarian stimulation, and, for that reason, it was concluded that the adrenal had not been stimulated and that the increase in 17-ketosteroids was of ovarian origin. The authors recognized that inconsistency of an increase in follicular activity following the administration of a luteinizing gonadotropin thought to be virtually free of FSH, and suggested several possible explanations. However, they did not consider the possibility that the estrogenic effects might be of adrenal origin. Certainly this could not be excluded since the adrenal cortex is known to contain estrogenic compounds? and to be capable of secreting them under some conditions.'
Recently Landau and his associates? studied the metabolic effects of chorionic gonadotropin in normal and eunuchoid men, and presented evidence to show that these effects were mediated through the testes. However, they recognized that minimal adrenal influences could not be excluded. Moreover, the possibility that these might be enhanced by more prolonged and intense gonadotropin stimulation must be considered, since these authors used relatively small doses, 14,000 international units in six days, an amount far less than that used in the present experiments or excreted in the average case of chorioepithelioma.
Tentatively, the adrenal cortex appears to be the most likely site of action of chorionic gonadotropin in producing gynecomastia. However, more direct proof of this hypothesis is still needed. A study of the effects of large doses of chorionic gonadotropin in castrates and in adrenalectomized males might serve to exclude the testis and establish the adrenal cortex as the pathway through which chorionic gonadotropin exerts its mammogenic effect. Unfortunately, it has not been possible for us to carry out such studies because of lack of suitable experimental subjects, but it is hoped that others who have access to such subjects may be able to do so. SUMMARY Large doses of chorionic gonadotropin, derived from human pregnancy urine and given over a relatively long period, produced gynecomastia in two cirrhotics, in a subject with congenital atrophy or aplasia of the testes, and in a patient with pituitary deficiency. In the two subjects studied serially there was a concomitant increase in 17-ketosteroid and estrogen excretion, which was also observed in a female cirrhotic control. However, there was little or no increase in androgen excretion by bioassay, and in none of the subjects with gynecomastia was there histological evidence of interstitial-or Sertoli-cell hyperplasia in the testis.
On the basis of these observations and a review of the pertinent literature the following tentative conclusions have been drawn: (a) The gynecomastia seen in association with chorioepitheliomas is probably related to the secretion of chorionic gonadotropin and not to any of the other hormones known to occur in such tissue.
(b) The colostrum-like secretion and the mammary alveolar development seen in some cases are probably due to progesterone, derived either from the tumor itself or from the adrenal cortex.
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(c) The effect of chorionic gonadotropin on the male mammary gland is not a direct one, but is probably mediated through.the pituitary, testes, or adrenal.
(d) The adrenal cortex is a likely site for this action, but further studies are needed to exclude other possibilities.
